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Abstract
Histone deacetylases (HDACs) act on histones within the nucleosome-bound promoter of human immunodefi-
ciency virus type 1 (HIV-1) to maintain proviral latency. HDAC inhibition leads to promoter expression and the
escape of HIV from latency. We evaluated the ability of the potent inhibitor recently licensed for use in oncology,
suberoylanilide hydroxamic acid (SAHA; Vorinostat), selective for Class I HDACs, to induce HIV promoter
expression in cell lines and virus production from the resting CD4þ T cells of antiretroviral-treated, aviremic HIV-
infected patients. In J89, a Jurkat T cell line infected with a single HIV genome encoding the enhanced green
fluorescence protein (EGFP) within the HIV genome, SAHA induced changes at nucleosome 1 of the HIV pro-
moter in chromatin immunoprecipitation (ChIP) assays in concert with EGFP expression. In the resting CD4þ T
cells of antiretroviral-treated, aviremic HIV-infected patients clinically achievable exposures to SAHA induced
virus outgrowth ex vivo. These results suggest that potent, selective HDAC inhibitors may allow improved
targeting of persistent proviral HIV infection, and define parameters for in vivo studies using SAHA.
Introduction
Upon human immunodeficiency virus type 1 (HIV-1)infection, a latently infected pool of resting CD4þ T cells
is established, making eradication of HIV infection impracti-
cal with current antiretroviral therapy (ART).1–3 Following
integration of viral DNA into the cellular genome, the HIV
long terminal repeat (LTR) promoter exists in a nucleosome-
bound conformation and is transcriptionally silent without
stimulation.4–6 Transcriptional activation of the HIV LTR in-
volves complex interactions between HIV regulatory proteins
and cellular transcription factors.
Eukaryotic DNA is condensed into chromatin of which the
basic unit, the nucleosome, consists of DNA wrapped around
an octamer of histone proteins. Post-translational modifica-
tions of histones are crucial for the regulation of gene ex-
pression. The amino acid tails of histones can be acetylated,
sumoylated, and ubiquitylated on lysine residues, methylated
on lysine or arginine residues, and phosphorylated on ser-
ine=threonine residues.7–14 These distinct modifications serve
to recruit specific regulatory complexes to DNA, which in
turn upregulate or downregulate gene expression.
Several studies provide evidence that histone deacetylases
(HDAC) are critical regulators of HIV latency. Human tran-
scription factors recruit the class I HDAC histone deacetylase
1 to the LTR. HDAC1 mediates chromatin remodeling re-
sulting in repression of LTR promoter expression and viral
production. The action of HDAC1 at the HIV-1 is required to
maintain proviral quiescence as HDAC inhibition leads to
LTR activation.15–18
HDAC1 can be recruited to the LTR by at least four mech-
anisms: by a complex containing the transcription factors YY1
and LSF, by a complex containing c-Myc and Sp1, by CBF-1,
or by the NF-kB p50 homodimer.17–21 Disruption of HDAC1
recruitment to the LTR or inhibition of this enzyme with the
weak HDAC inhibitor valproic acid (VPA) induces viral out-
growth from resting CD4þ T cell of aviremic HIV-infected
individuals on ART.22–24
These observations led to the exploration of HDAC inhibi-
tors as a potential therapeutic modality to disrupt latent HIV
infection. The administration of valproic acid with intensi-
fied ART to aviremic, ART-treated HIV-infected individuals
led to a depletion of resting cell infection (RCI) in three of
four patients.25 However, further studies by our group and
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others26–28 found infrequent and modest depletion of RCI in
patients on standard ART treated with valproic acid. As val-
proic acid is a weak and nonspecific HDAC inhibitor, we
explored the potential of a more potent and selective HDAC
inhibitor for use as a therapeutic tool to target persistent HIV
infection.
Suberoylanilide hydroxamic acid (SAHA; vorinostat) is a
member of the hydroxamic acid class of HDAC inhibitors.29
This potent HDAC inhibitor was recently approved by the
FDA for the treatment of cutaneous T cell lymphoma.30,31
SAHA is selective for the Class 1 HDACs 1, 2, 3, and 8, has
some activity against the Class II HDACs 6, 10, and 11, but no
activity at clinically achievable concentrations against the
Class II HDACs 4, 5, 7, and 9.
Class I HDACs regulate HIV LTR expression.17–21,32
Therefore SAHA may offer the possibility of modulating HIV
gene expression, but with fewer effects on host genes than
would be induced by global, nonselective HDAC inhibition.
We evaluated the ability of SAHA to remodel chromatin
about the HIV promoter, induce HIV promoter expression in
cell lines, and allow virion recovery from the resting CD4þ T
cells of aviremic HIV-infected individuals. Our findings pro-
vide a rationale for the study of the effect of SAHA in com-
bination with ART on persistent HIV infection in aviremic
HIV-infected patients.
Materials and Methods
Cell culture and chromatin immunoprecipitation (ChIP)
J89 cells33 and peripheral blood mononuclear cells (PBMCs)
were cultured as described.27,34 Four million J89 cells were
washed with phosphate-buffered saline (PBS) and incubated
with 3 mM VPA (Sigma, St. Louis MO) or 500 nM SAHA (gift
of Merck Research Laboratories, West Point, PA) or in media
alone for 4 h. ChIP was performed as described34 with the
following modifications. Sonicated cell lysates were centri-
fuged and 80–100 mg of soluble chromatin was incubated
overnight with 5ml of anti-acetyl histone 3 or anti-acetyl his-
tone 4 (Ac-H3, Ac-H4, Milipore) or 5 ml of anti-HDAC-1
(Abcam, Cambridge, MA) or rabbit preimmune immuno-
globulin G (Sigma). PCR was carried out with the following
primers: LTR-109F (50-TACAAGGGACTTTCCGCTGG-30)
and LTRþ82R (50-AGCTTTATTGAGGCTTAAGC-30).
A quantitative real-time PCR assay of the products of ChIP20
was performed to verify the significance of changes in the
occupancy of HDAC1 and acetylated histones at the HIV-1
LTR region using the following primers: LTRrt9 forward (50-
AGCCCTCAGATGCTACATATAAGCA-30) and LTRrt8 (50-
TAGCCAGAGAGCTCCCAGGCTCAGA-30). The percent of
input HIV LTR DNA was determined by comparing the cycle
threshold values of each reaction to a standard curve gener-
ated from input DNA. Fold change in occupancy of acetylated
histones and HDAC1 at the LTR relative to untreated control
was calculated after subtracting background immunoprecip-
itation measured with nonspecific IgG.
LTR-driven GFP mRNA measurements
J89 cells were incubated with selected drug concentrations
for 4–5 h. Cells were washed and snap frozen on an ethanol
dry ice bath and stored at808C until use. Cells were thawed
on ice and RNA was isolated using the RNeasy RNA isolation
kit (Qiagen, Valencia, CA) according to the manufacturer’s
protocol. cDNA was synthesized using Superscript II (In-
vitrogen). Semiquantitative PCR for EGFP was performed us-
ing a set of primers as previously reported.35 Endogenous
GAPDH was measured on the same cDNA samples using the
following primers: GAPDH-RT-FOR, 50-CCATGGAGAAG
GCTGGGG-30 and GAPDH-RT-REV, 50-CAAAGTTGTCAT
GGATGACC-30. PCR products were resolved in an 8% aga-
rose gel, visualized by ethidium bromide staining, and ana-
lyzed by GeneTools. Fold GFP enrichment was determined by
normalizing to GAPDH and differences (n-fold) relative to
untreated control were calculated.
To measure proliferation and viability of PBMCs and J89
cells in the presence of drugs, cells were subjected to an MTT
assay using a cell proliferation kit following the manufactur-
er’s instructions (Roche Applied Sciences, Indianapolis, IN).
The percentage of cells proliferating was calculated from cells
cultured in drug-free medium.
Limiting dilution cultures of latently infected CD4þ
T cells from HIV-infected donors
Lymphocytes were obtained by continuous-flow leuko-
pheresis. Isolation of resting CD4þ T cells and recovery and
quantification of replication-competent virus were performed.
Briefly, PBMCs were isolated from the apheresis product by
Ficoll gradient and resting CD4þ T cells were purified by
negative selection as previously described.23,25,27 Purity of
isolated resting T cells was determined by flow cytometry;
cells were routinely>98% CD4þ, and less than 0.5% expressed
activation markers.
Following purification, resting CD4þ T cells were incu-
bated for 2 days with the HIV integrase inhibitor L-870812
and either efavirenz or abacavir as described.27 Cells were
then plated in replicate dilutions of 2.5 million, 0.5 million,
and 0.1 million to allow estimation of the frequency of RCI.
Maximal mitogen stimulation has been widely used to quan-
titate the frequency of resting cell infection, and so cells were
stimulated with 1mg= ml PHA-L (Remel), a 5-fold excess of
allogeneic irradiated PBMCs from a seronegative donor, and
100 U=ml IL-2. To measure the frequency of outgrowth after
HDAC inhibition, cells were exposed to either 40 mM VPA or
250–335 nM SAHA. The concentration of SAHA and VPA
was selected after measuring free drug concentration in tis-
sue culture conditions (data not shown) choosing concentra-
tions comparable to free drug concentrations achievable in
patients.
Further, to ensure that outgrowth was not attributed to rare
nonresting infected cells that might exist within such a large
number of cells, cells were cultured in parallel in the presence
of 20 U=ml of IL-2. If the frequency of outgrowth in the pres-
ence of this ‘‘survival’’ concentration of IL-2 was within
0.3 log10 of the frequency of outgrowth in the presence of VPA
or SAHA, outgrowth in the presence of HDAC inhibitor was
considered nonspecific and nonsignificant. This occurred only
rarely, and only in patients in which the frequency of resting
cell infection was very low. As previously,27 HIV seronegative
PBMCs screened for adequate CCR5 expression following
PHA stimulation were collected by leukopheresis and stored
in aliquots, and assays were performed with matched patient
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sample-donor aliquot pairs to reduce interassay variation. A
maximum likelihood method was used to calculate the in-
fectious units per billion of resting CD4þ T cells after exposure
to PHA or SAHA.36
Results
SAHA induces chromatin changes at the HIV LTR
leading to LTR expression
As HIV integrants are too rare in patients’ cells to study
chromatin, we studied modification induced by SAHA at the
LTR in J89 cells, a latently infected Jurkat T cell line with a
complete integrated proviral genome.33 The viral genome also
encodes EGFP as a marker for HIV-LTR expression. We com-
pared the ability of SAHA and VPA to induce acetylation of
Nuc 1 and to alter HDAC1 recruitment to the Nuc-1 region as
measured by ChIP. Cells were assayed after only 4 h of
treatment to avoid assaying effects due to host cell cycling or
secondary changes in host gene expression.
J89 cells were harvested for ChIP after 4 h in media, 3 mM
VPA, or 500 nM to 1mM SAHA and DNA products were
quantitated by real-time PCR. A representative assay is shown
in Fig. 1. Both SAHA and VPA induced an increase in acety-
lation of histone 3 at the HIV-LTR Nuc-1 (10.1-fold for SAHA).
Similarly, occupancy of HDAC1 was decreased (31.3-fold for
SAHA) as we have previously described after VPA expo-
sure.18 Similar results were obtained when the acetylation of
histone 4 was measured (data not shown).
We then compared LTR-driven GFP mRNA expression in
J89 cells treated with SAHA and VPA. Again cells were assayed
after only 4 h of treatment. Total RNA was extracted and GFP
RNA expression was measured by PCR. As shown in Fig. 2,
after only 4 h of exposure, both SAHA and VPA induced LTR-
driven GFP mRNA expression. Consistent with the greater
potency of SAHA, GFP was induced by nanomolar concen-
trations of SAHA, as compared to millimolar concentrations
of VPA. Similarly, both SAHA and VPA induced LTR-driven
GFP protein expression (not shown).
SAHA induces virus outgrowth from resting
CD4þ T cells of aviremic HIV-infected individuals
Lymphocytes were obtained by leukopheresis from five
aviremic HIV-infected patients with CD4 T cell counts rang-
ing from 529 to 960 cells=ml. Using a rigorous assay to quan-
titate resting CD4þ cell HIV infection, we tested the ability of
SAHA to induce HIV expression in patients’ resting T cells.23
SAHA is primarily bound to albumin. In human plasma,
71% of SAHA is protein bound. When measured in tissue
culture media with 10% FCS, only 5% of VPA is protein bound
(data not shown). Although no such data exist for SAHA in
culture media, we have conservatively assumed a similar de-
gree of protein binding. Protein-unbound peak concentrations
of SAHA in patients given a 400 mg dose are estimated to be
340 nM (Vorinostat Package Insert, Merck & Co., 2006). To
approximate this exposure in vitro, we tested 250–335 nM
SAHA in tissue culture (238–318 nM unbound drug concen-
tration). These concentrations do not significantly affect J89
cell or PBMC proliferation (Fig. 3). Micromolar concentrations
of SAHA are generally required to induce tumor cell apo-
ptosis in vitro.37
Under these conditions, SAHA induced virus outgrowth in
four of five patients assayed, although not always at the fre-
quency seen after maximal mitogen stimulation (Table 1). The
frequency of RCI in patients 1 and 3 was measured at two
separate time points a month or more apart, and virus was
recovered with comparable frequency in separate assays.
Given the 0.3 log variance of our assay,27 recovery of HIV after
exposure to SAHA was similar to that following 24 h of
maximal stimulation in patients 2–4, and somewhat less fre-
quent in patient 1. In a patient with low RCI (patient 5) as
measured by maximal mitogen stimulation, virus recovery
was not above background levels seen in the presence of the
concentration (20 U=ml) of IL-2 used to promote cell survival.
Further, to model the effect that a clinical dose of SAHA
might have in vivo, we measured the effect of ex vivo exposure
to the drug. SAHA has a short half-life in vivo, and when
measured in cancer patients receiving multiple doses of
FIG. 1. Like VPA, SAHA increases acetylation of Nuc 1 and
decreases HDAC-1 occupancy at the HIV-1 LTR. J89 cell
treated with media, 3 mM VPA, or 500 nM SAHA for
4 h were assayed by chromatin immunoprecipitation with
anti-acetylated H3, anti-HDAC-1. To demonstrate that the
apparent quantitative changes are significant in this semi-
quantitative assay, DNA products of ChIP were quantitated
in triplicate by real-time PCR. Assays are representative of 3
independent experiments, and real-time quantitation of the
fold change relative to untreated control is shown.
FIG. 2. SAHA activates HIV LTR transcription. J89 cells
were treated with the indicated concentrations of SAHA or
VPA for 4hrs. Semi-quantitative RT PCR was performed on
total RNA isolated from treated and untreated cells as de-
scribed in methods. The data presented is the mean SE of 3
independent experiments.
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400 mg=day in the fed state was 2 h (Vorinostat Package In-
sert, Merck & Co., 2006). To model the effect of a clinical
exposure to SAHA, we measured the frequency of recoverable
virus after a similar, pulsatile exposure of resting CD4þ cells
to the HDAC inhibitor. Resting cells from two additional
patients were exposed to SAHA for 3 or 6 h. Cells were then
washed and cocultured with CD8-depleted PBMCs as de-
scribed above. Virus outgrowth after pulsatile exposure was
compared to viral recovery from cells continuously exposed
to mitogen stimulation for 24 h as per standard assay condi-
tions (Table 2). In both patient samples, pulsatile exposure to
SAHA simulating clinical dosing allowed recovery of HIV
from resting CD4þ T cells. As fewer cells were available from
these patients, we cannot quantitatively compare the fre-
quency of RCI; its point estimate is less accurate. Never-
theless, the frequency of virus recovery after a brief exposure
to SAHA was above that of background IL-2.
Ideally, a drug employed to reduce persistent HIV infection
in patients must not induce the expression of activation
markers or upregulate the expression of HIV entry coreceptors
on uninfected cells, as this would render these cells more
susceptible to de novo infection. To determine the effect of
SAHA on cell surface activation markers, PBMCs were ex-
posed to concentrations of SAHA used in resting cell assay in
the presence of IL-2, and cell surface markers were assayed.
Results were compared to cells stimulated with mitogen and
IL-2 or IL-2 alone. Exposure of PBMCs to 335 nM SAHA did
not significantly alter the expression of CXCR4, CCR5, CD69,
and Ki67 when compared to cells exposed to control IL-2 and
mitogen (data not shown). Finally, there was no difference in
HIV p24 antigen output in either activated or resting cells that
were infected in the presence or absence of SAHA (data not
shown).
Discussion
A long-lived latently infected population of resting mem-
ory T cells, unaffected by both the immune response and
antiretrovirals, is established early during infection. Therapies
that target this persistent reservoir are necessary if HIV in-
fection is to be eradicated. One mechanism that maintains
proviral quiescence in resting CD4þ T cells is the activity of
HDACs at the viral promoter.
We investigated the ability of SAHA, a potent HDAC in-
hibitor, to induce LTR expression in a cell line model of la-
tency and to induce virus from CD4þ resting T cells of
aviremic HIV-infected individuals. Our results illustrate that
SAHA exposure leads to chromatin acetylation at nucleosome
1 and decreased HDAC1 occupancy. This is consistent with
the known counterregulatory interactions of HDACs and
histone acetyltransferases,38 and results in HIV transcription
and virus production in a chronically infected, transcription-
ally quiescent cell line. Ideally, it would be desirable to mea-
sure chromatin changes in infected resting CD4þ T cells from
aviremic HIV-infected individuals. However, given the low
frequency of such cells, such an assay is not technically fea-
sible.
Clinically relevant concentrations of SAHA induce virus
outgrowth ex vivo from resting T cells of aviremic HIVþ pa-
tients. Indeed, given the short half-life of SAHA it is notable
FIG. 3. Toxicity of SAHA in seronegative donor PBMC and
J89 cells. PBMC or J89 cells were cultured in the absence or
presence of SAHA or VPA at the indicated concentrations.
MTT assays were performed as described in methods. The
percentage of proliferating cells was calculated compared to
cells cultured in standard media. The data represent the
mean SE of 3 independent experiments.
Table 1. Recovery of HIV from Resting CD4þ T Cells
Isolated from Aviremic, ART-Treated, HIV-Infected
Individuals after Exposure to SAHA, VPA, or Maximal
Mitogen Activation
Infected units per billion of HIVþ donor resting CD4þ T cells








1visit A 3560 >3560 17950
1visit B 4540 3220 11340
2 543 703 1243
3visit A 561 Not done 487
3visit B 410 223 440
4 280 179b 426
5 Not recoveredc Not recovered 45
aPHA 1mg=ml, IL2 100 U=ml, 5-fold excess irradiated allogeneic
cells.
bFrequency of HIV outgrowth not above background (IL-2 only
control).
cPatients 1 and 2: 335 nM; patients 3–5: 250 nM.
Table 2. Recovery of HIV from Resting CD4þ T Cells
Isolated from Aviremic, ART-Treated, HIV-Infected
Individuals after a 3- or 6-h Pulsed Exposure to
SAHA Compared to 24 h Exposure to Maximal
Mitogen Activation
Infected units per billion resting CD4þ T cells
Patients SAHAa Maximal mitogenb
6 162 (3 h) 1160 (24 h)
7 295 (6 h) 360 (24 h)
aPatient 6 250 nM SAHA; patient 7 335 nM SAHA.
bPHA 1mg=ml, IL-2 100 U=ml, 5-fold excess irradiated allogeneic
cells.
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that even a brief exposure to the HDAC inhibitor is sufficient
to allow recovery of replication-competent HIV from patients’
cells. The effect of SAHA on histone acetylation and virus
outgrowth is achieved using nanomolar concentrations of the
drug that are durably achieved in the clinical administration
of the drug.
SAHA is known to alter the expression of 2–10% of the
genome in transformed cell lines.29 However, the effect of
SAHA on the expression of surface activation markers in cells
of hematopoietic lineage was not known. The ideal drug used
to purge persistent HIV infection should not render bystander
cells more susceptible to de novo infection by inducing ex-
pression of cell surface activation markers. Exposures to
SAHA do not upregulate either surface markers of activation
in PBMCs or receptors for HIV infection. Further, virion
production following de novo infection was not affected by
SAHA.
In cells from some patients, but not all, recovery of HIV
after SAHA exposure was comparable to recovery after max-
imal mitogen stimulation. These studies cannot yet address
whether additional signals, such as those that activate NF-kB
signaling, will be required to fully purge infection in resting
CD4 cells.
Clearance of HIV infection should be a therapeutic goal,
although it may be a distant one. Chronic suppressive anti-
viral therapy is complex and fraught with toxicities and costs.
Selective induction of latent HIV might allow antiretrovirals
and the immune response to clear HIV infection. Therapies
with potent and selective HDAC inhibitors such as SAHA in
combination with intensified ART may allow efficient clear-
ance of persistent HIV infection.
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